Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Keith D. Eaton"'
Autor:
Cameron Chalker, Jenna M. Voutsinas, Qian Vicky Wu, Rafael Santana‐Davila, Victoria Hwang, Christina S. Baik, Sylvia Lee, Brittany Barber, Neal D. Futran, Jeffrey J. Houlton, George E. Laramore, Jay Justin Liao, Upendra Parvathaneni, Renato G. Martins, Keith D. Eaton, Cristina P. Rodriguez
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4104-4111 (2022)
Abstract Background Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance
Externí odkaz:
https://doaj.org/article/53da6a9d3e554131937be881d3ebe09e
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100419- (2022)
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory chan
Externí odkaz:
https://doaj.org/article/3a4efa3de5bb479a87cf79b15716c037
Autor:
Stephen R. Bowen, PhD, Daniel S. Hippe, MS, Hannah M. Thomas, PhD, Balukrishna Sasidharan, MBBS, MD, DNB, DMRT, Paul D. Lampe, PhD, Christina S. Baik, MD, MPH, Keith D. Eaton, MD, PhD, Sylvia Lee, MD, Renato G. Martins, MD, MPH, Rafael Santana-Davila, MD, Delphine L. Chen, MD, Paul E. Kinahan, PhD, Robert S. Miyaoka, PhD, Hubert J. Vesselle, MD, PhD, A. McGarry Houghton, MD, Ramesh Rengan, MD, PhD, Jing Zeng, MD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 2, Pp 100857- (2022)
Purpose: We sought to examine the prognostic value of fluorodeoxyglucose-positron emission tomography (PET) imaging during chemoradiation for unresectable non-small cell lung cancer for survival and hypothesized that tumor PET response is correlated
Externí odkaz:
https://doaj.org/article/3fb66f4cd14d4b90978539f30c9d469e
Autor:
Perrin E. Romine, Renato G. Martins, Keith D. Eaton, Douglas E. Wood, Fatemeh Behnia, Bernardo H. L. Goulart, Michael S. Mulligan, Sarah G. Wallace, Elizabeth Kell, Julie E. Bauman, Shilpen A. Patel, Hubert J. Vesselle
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value
Externí odkaz:
https://doaj.org/article/0b333ebbba4a47c1b41710fc169460fd
Autor:
Christina Baik, Sylvia Lee, Kitty Cook, Sarah Wallace, Rebecca Wood, Rafael Santana-Davila, Laura Chow, Cristina Rodriguez, Keith D. Eaton, Renato Martins
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100416- (2021)
Background: Patients with metastatic non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation have effective targeted therapy options initially but most patients eventually progress and receive cytotoxic chemotherapy. In this single-i
Externí odkaz:
https://doaj.org/article/2da1ef609e36486eb9cf2aa0152480ca
Autor:
Keith D. Eaton, Christina S. Baik
Publikováno v:
Cancers, Vol 4, Iss 4, Pp 969-988 (2012)
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a high
Externí odkaz:
https://doaj.org/article/a49e42938a854cf7820e95e0a45f895f
Autor:
Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard Chao, Balazs Halmos
Publikováno v:
Clinical Lung Cancer. 24:218-227
Autor:
Perrin E. Romine, Qin Sun, Catherine Fedorenko, Li Li, Mariel Tang, Keith D. Eaton, Bernardo H.L. Goulart, Renato G. Martins
Publikováno v:
JCO Oncol Pract
PURPOSE: Time from diagnosis to treatment has been associated with worse survival outcomes in non–small-cell lung cancer (NSCLC). However, little is known about the impact of delay in time to diagnosis. We aimed to evaluate the impact of time from
Autor:
Cristina Merkhofer, Renato G. Martins, Scott D. Ramsey, Keith D. Eaton, Bernardo H. L. Goulart
Publikováno v:
Clin Lung Cancer
Introduction The impact of clinical trial participation on overall survival is unclear. We hypothesized that enrollment in a therapeutic drug clinical trial is associated with longer overall survival in patients with metastatic non-small cell lung ca
Autor:
Renato G. Martins, Cristina Merkhofer, Bernardo H. L. Goulart, Keith D. Eaton, Shasank Chennupati, Scott D. Ramsey, Qin Sun
Publikováno v:
JCO Oncol Pract
PURPOSE: The costs associated with clinical trial enrollment remain uncertain. We hypothesized that trial participation is associated with decreased total direct medical costs to health care payers in metastatic non–small-cell lung cancer. METHODS: